Published on December 18, 2024 in the Journal of Clinical Oncology, the phase III postMONARCH trial presents compelling data on abemaciclib + fulvestrant for patients with advanced breast cancer who progressed on prior CDK4/6 inhibition plus endocrine therapy.
The study demonstrated that continuing CDK4/6 inhibition with a switch in endocrine therapy significantly improved progression-free survival compared to fulvestrant alone (HR 0.73, P = .017). This benefit was consistent across clinical and genomic subgroups including those with ESR1 or PIK3CA mutations offering a new line of targeted treatment for a patient population with limited post-progression options.
Congratulations to the lead author Dr. Kevin Kalinsky and all co-authors, including Dr. Erika Hamilton, Dr. Umut Demirci, Dr. Miguel Martin, and many others for their work on this important research advancing care in hormone receptor–positive, HER2-negative breast cancer.
Full article: https://lnkd.in/dpXmuEBU
